anti-CD19-CAR CMV-specific T lymphocytes

A preparation of human cytomegalovirus (CMV)-specific T lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-CAR CMV-specific T lymphocytes recognize, bind to, and induce selective toxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. The anti-CD19-CAR CMV-specific T lymphocytes may potentially be expanded in vivo through CMV vaccination.